Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
InnoPharma receives FDA approval for generic DACOGEN

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN. [More]
HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI). [More]
Suggestions for successful breast feeding from nurse midwifery program

Suggestions for successful breast feeding from nurse midwifery program

Most new moms know the benefits of breast feeding. For babies, it can lower the risk of developing asthma, diabetes, and leukemia. For moms, it reduces the risk of breast cancer. But many women still don't know where to turn for help when breast feeding doesn't go as smoothly as they imagined it would. [More]
Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Scientists searching for new drugs to fight malaria have identified a number of compounds -- some of which are currently in clinical trials to treat cancer -- that could add to the anti-malarial arsenal. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine. [More]
Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Virginia lawmakers will convene in a special session next month to address the question of expanding Medicaid and, more broadly, the fact that hundreds of thousands of poor and disabled people in the state have no health insurance coverage. Democrats and some moderate Republicans have advanced a variety of ideas to tackle that problem. Conservative Republicans, who control the legislature in Richmond, have rejected those solutions while proposing no alternative. Does the GOP intend for the special session to be anything more than a charade at taxpayers' expense? (8/15). [More]
Natural killer cells can be used to combat acute lymphoblastic leukemia

Natural killer cells can be used to combat acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells. [More]
Research findings may lead to novel target for chemoresistant cancer cells

Research findings may lead to novel target for chemoresistant cancer cells

Dartmouth cancer researchers at Norris Cotton Cancer Center found a means of causing the elimination of a protein that maintains cancer cell viability; the results of the study appear in the August 8 issue of The Journal of Biological Chemistry. [More]
HDAC inhibitors may also be effective against kidney stones

HDAC inhibitors may also be effective against kidney stones

Anyone who has suffered from kidney stones is keenly aware of the lack of drugs to treat the condition, which often causes excruciating pain. [More]
AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

Retinoic acid is a form of vitamin A that is used to treat and help prevent the recurrence of a variety of cancers, but for some patients the drug is not effective. [More]
Researchers find crucial signaling pathway that helps HSCs to generate

Researchers find crucial signaling pathway that helps HSCs to generate

Hematopoietic stem cells (HSCs) give rise to all other blood cell types, but their development and how their fate is determined has long remained a mystery. [More]
New approach to predict myeloma patients using calcium isotope analysis

New approach to predict myeloma patients using calcium isotope analysis

A team of researchers from Arizona State University and Mayo Clinic is showing how a staple of Earth science research can be used in biomedical settings to predict the course of disease. [More]
Epigenetics has a large say in blood formation

Epigenetics has a large say in blood formation

Blood stem cells have the potential to turn into any type of blood cell, whether it be the oxygen-carrying red blood cells, or the many types of white blood cells of the immune system that help fight infection. [More]
Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014. [More]
Scientists solve key mystery in cancer research

Scientists solve key mystery in cancer research

A chance meeting between two leading UK and US scientists could have finally helped solve a key mystery in cancer research. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. [More]